Market Cap
$66.9M
PLRX
PLIANT THERAPEUTICS, INC.
$1.03 ▼ -1.90%
Prev close $1.05Market cap$66.9M
12-mo target$2.00 (+94.2%)
High Impact Filing (7/10)12 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PLRX right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$21.0M
Inst. Activity
2 buys / 12 sells
Social Sentiment
60° Warm
SEC Reports
6
Press Releases
1
Price chart 30d -11.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 other
Aug 18, 2026 Press Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmace
Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refract
Impact 4/10
Jul 9, 2026 Insider
Iannone Robert was granted 60,000 shares
Director
Jul 9, 2026 Insider
Borellini Flavia was granted 60,000 shares
Director
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — TRIM
2,142,226 shares ($2.4M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
578,577 shares ($660.0K)
Jun 11, 2026 Insider
May 11, 2026 SEC Huh Hoyoung was granted 70,000 shares
Director
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue bio
PRESS-RELEASE — Impact 6/10
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Hold | 47% |
| Mar 12, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Nov 7, 2025 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Oct 10, 2025 | JP Morgan | DOWNGRADE | Underweight | 55% |
| Aug 8, 2025 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Mar 18, 2025 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Mar 4, 2025 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Mar 4, 2025 | Citigroup | MAINTAIN | Neutral | 55% |
| Mar 4, 2025 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Mar 4, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 6 | 2 | 2 | 0% | |
| Aug 1, 2026 | 0 | 0 | 6 | 2 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 6 | 2 | 2 | 0% | |
| Jun 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| May 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| Apr 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| Mar 1, 2026 | 0 | 1 | 7 | 2 | 2 | 8% | |
| Feb 1, 2026 | 0 | 1 | 7 | 2 | 2 | 8% |
Price targets
Where 1 covering analysts think PLRX trades over the next 12 months.
$2.00 +94.2% upside Strong Buy
Current$1.03 Low$2.00 Median$2.00 High$2.00 1 analysts
$2.00$2.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 3 neutral · avg impact 5.0/10.Plus 1 press releases.
BEARISHPRESS-RELEASE6/10
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was
May 11, 2026
NEUTRAL8-K4/10
Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower than
May 11, 2026
MIXED8-K6/10
Pliant Therapeutics announced the retirement of three board members effective at the 2026 Annual Mee
Apr 17, 2026
NEUTRALEFFECT4/10
Pliant Therapeutics' $300 million shelf registration, including a $50 million at-the-market (ATM) of
Apr 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
other
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise
Aug 25, 2026
Clinical Trial
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Phase Phase 2 — TERMINATED
Aug 18, 2026
fda
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track desi
Aug 10, 2026
earnings_calendar
PLRX Q2 2026 Earnings Scheduled — 2026-08-10
Aug 5, 2026
earnings_calendar
PLRX Q2 2026 Earnings Scheduled — 2026-08-05
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.37 | $-0.39–$-0.36 | 13.9% | -1.7% | 0↑ 2↓ | $0.0B | 3 |
| Next Q | $-0.37 | $-0.39–$-0.36 | -4.7% | +1.5% | 2↑ 2↓ | $0.0B | 3 |
| Current FY | $-1.43 | $-1.47–$-1.41 | 40.4% | -1.6% | 2↑ 2↓ | $0.0B | 3 |
| Next FY | $-1.28 | $-1.47–$-0.94 | 10.4% | -59.0% | 2↑ 2↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.370 | — |
| 7d ago | $-0.383 | +0.012 |
| 30d ago | $-0.364 | -0.006 |
| 60d ago | $-0.364 | -0.006 |
| 90d ago | $-0.364 | -0.006 |
Institutional ownership
Which big funds own PLRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $21.0M total value (18,393,882 shares) as of 2026-Q2. Top holders: VANGUARD, TWO, CITADEL. Net selling activity: 12 institutions trimmed/exited vs 2 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 2,440,351 | $2.8M | 13.3% | — |
| TWO SIGMA INVESTMENTS, LP | 2,262,832 | $2.6M | 12.3% | — |
| CITADEL ADVISORS LLC | 2,142,226 | $2.4M | 11.6% | TRIM -33.6% |
| RENAISSANCE TECHNOLOGIES LLC | 2,049,874 | $2.3M | 11.1% | ADD +77.2% |
| Woodline Partners LP | 1,296,534 | $1.5M | 7.0% | TRIM -55.0% |
| BlackRock, Inc. | 1,151,214 | $1.3M | 6.3% | — |
| MARSHALL WACE, LLP | 835,124 | $952.0K | 4.5% | DOUBLED +260.7% |
| JPMORGAN CHASE & CO | 681,647 | $783.9K | 3.7% | TRIM -28.9% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 643,120 | $733.2K | 3.5% | ADD +29.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 578,577 | $660.0K | 3.1% | ADD +38.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | TRIM | 3,226,599 | 2,142,226 | -33.6% | $2.4M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 417,274 | 578,577 | +38.7% | $660.0K |
| UBS Group AG | TRIM | 1,057,954 | 571,760 | -46.0% | $651.8K |
| MILLENNIUM MANAGEMENT LLC | TRIM | 1,180,518 | 559,447 | -52.6% | $637.8K |
| MORGAN STANLEY | TRIM | 505,739 | 298,976 | -40.9% | $340.8K |
| GOLDMAN SACHS GROUP INC | TRIM | 596,837 | 208,585 | -65.1% | $237.8K |
| JANE STREET GROUP, LLC | TRIM | 356,794 | 129,951 | -63.6% | $148.1K |
| Squarepoint Ops LLC | TRIM | 163,215 | 40,814 | -75.0% | $46.5K |
| Quadrature Capital Ltd | TRIM | 50,981 | 33,280 | -34.7% | $37.9K |
| FEDERATED HERMES, INC. | TRIM | 62,651 | 29,055 | -53.6% | $33.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 48 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Iannone Robert | Director | AWARD | 60,000 | — | — |
| Jul 9, 2026 | Borellini Flavia | Director | AWARD | 60,000 | — | — |
| Jun 11, 2026 | Huh Hoyoung | Director | AWARD | 70,000 | — | — |
| Jun 11, 2026 | Cline Darren S | Director | AWARD | 70,000 | — | — |
| Jun 11, 2026 | Curnutte John T | Director | AWARD | 70,000 | — | — |
| Jun 11, 2026 | Krognes Steve E. | Director | AWARD | 70,000 | — | — |
| Jun 11, 2026 | MCCOURT Thomas A | Director | AWARD | 70,000 | — | — |
| Jun 11, 2026 | CROWELL GAYLE A | Director | AWARD | 70,000 | — | — |
| Apr 17, 2026 | Cummings Keith Lamont | Chief Financial Officer | D | 76,047 | — | — |
| Apr 17, 2026 | Cheung Lily | Chief Human Resource Officer | D | 123,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PLRX.
Shares short
3,692,416
Settlement Sep 15, 2026
Change vs prior
+12.6%
Semi-monthly cycle
Days to cover
8.9
At avg daily volume
Of shares outstanding
≈6.0%
Estimate — not % of float
All PLRX filing & press-release reports (7)
- PRESS-RELEASE reportAug 18, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportMay 11, 2026
- 8-K reportApr 17, 2026
- EFFECT reportApr 7, 2026
- 8-K reportMar 11, 2026
- 8-K reportMar 3, 2026